KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

Abstract Background KRAS-mutant non-small cell lung cancer (NSCLC) shows a relatively low response rate to chemotherapy, immunotherapy and KRAS-G12C selective inhibitors, leading to short median progression-free survival, and overall survival. The MET receptor tyrosine kinase (c-MET), the cognate re...

Full description

Bibliographic Details
Main Authors: Rafael Rosell, Eloisa Jantus-Lewintre, Peng Cao, Xueting Cai, Baojuan Xing, Masaoki Ito, Jose Luis Gomez-Vazquez, Mireia Marco-Jordán, Silvia Calabuig-Fariñas, Andrés Felipe Cardona, Jordi Codony-Servat, Jessica Gonzalez, Kevin València-Clua, Andrés Aguilar, Carlos Pedraz-Valdunciel, Zahra Dantes, Anisha Jain, S Chandan, Miguel Angel Molina-Vila, Oscar Arrieta, Macarena Ferrero, Carlos Camps, Maria González-Cao
Format: Article
Language:English
Published: BMC 2024-06-01
Series:Cell Communication and Signaling
Online Access:https://doi.org/10.1186/s12964-024-01667-x

Internet

https://doi.org/10.1186/s12964-024-01667-x

Similar Items